Severe dengue is a cause of admission to critical care, especially in pediatric cases, and during epidemic outbreaks. Fluid support is basically the therapy offered, due to a scarcity of antiviral or immunological options to modulate the disease. Dengue is an endemic condition in tropical and subtropical regions as Villavicencio, and local ICUs provide care to the adult and pediatric population from the city and distant surrounding areas. National and international agencies' clinical guidelines have standard recommendations for the therapy of dengue shock syndrome (DSS), but data about performance is not available. Severity, organ dysfunction, hemorrhagic events, and capillary leak are predictors for decease. There are several epidemiological trials about dengue in the region, although publications about the characteristics of patients in ICU are nearly null. Currently, there is enough human resources and technology in ICU to provide an optimal care in cases of severe dengue. There is a need to recognize most appropriate strategies for the treatment of the disease, and their results, to adjust and provide better outcomes.
The aim of the study is to analyze the characteristics of patients with severe dengue admitted to the intensive care unit, to contribute to knowledge and better understanding of the disease in a specific clinical environment.
An observational retrospective study will be designed by the analysis of the ICU database of hospitals from Villavicencio, Colombia, since January to May 2023. The records of patients admitted with a diagnose of severe dengue will be exported to Excel for reviewing and debugging. Demographic information, laboratory results, severity scores, and outcomes will be examined. Categorical variables will be described by frequency and proportion; quantitative variables will be defined in a central and dispersion distribution. Chi-square and Mann-Whitney U test will be used to compare, according to the characteristics of the outcome.
It will be a pioneer study at this region, and it is necessary to determine the characteristics of patients admitted to the intensive care unit, the care provided, and the results of the treatment.

Start Date01 Jul 2023

Sponsor / Collaborator-

ChiCTR2200063339 / SuspendedPhase 4IIT

Study on the value of Docusate Sodium in the patients who failed the first bowel preparation

Start Date01 Sep 2022

Sponsor / Collaborator

Shanghai No. 10 People's Hospital

NCT05423249 / RecruitingNot ApplicableIIT

Treatment of Non-Anemic Iron Deficiency in Pregnancy: a Double-Blind Randomized Control Trial

The objective is to investigate the treatment of non-anemic iron deficiency (NAID) and the impact on development of anemia later in pregnancy. Anemia in the third trimester has been identified as a risk factor for maternal and fetal morbidity that might lead to mortality. Due to the high incidence of NAID in pregnancy, there is an opportunity for early screening and treatment to decrease progression to anemia. The primary aim of this study is to establish if treatment of NAID will result in higher third trimester hemoglobin values and decrease incidence of anemia at term.

Start Date12 Aug 2022

Sponsor / Collaborator

Stony Brook University

100 Clinical Results associated with Dioctyl Sodium Sulfosuccinate

100 Translational Medicine associated with Dioctyl Sodium Sulfosuccinate

100 Patents (Medical) associated with Dioctyl Sodium Sulfosuccinate

5,110

Literatures (Medical) associated with Dioctyl Sodium Sulfosuccinate

31 Dec 2024·Gut microbes

DSS treatment does not affect murine colonic microbiota in absence of the host

Article

Author: Herberth, Gunda ; Lehmann, Jörg ; Krause, Jannike Lea ; Chang, Hyun-Dong ; Slanina, Ulla ; Hoffman, Maximillian ; Schaepe, Stephanie Serena ; Zenclussen, Ana Claudia ; Rolle-Kampczyk, Ulrike ; Jehmlich, Nico ; Haange, Sven-Bastiaan ; von Bergen, Martin ; Engelmann, Beatrice

The prevalence of inflammatory bowel disease (IBD) is rising globally; however, its etiology is still not fully understood. Patient genetics, immune system, and intestinal microbiota are considered critical factors contributing to IBD. Preclinical animal models are crucial to better understand the importance of individual contributing factors. Among these, the dextran sodium sulfate (DSS) colitis model is the most widely used. DSS treatment induces gut inflammation and dysbiosis. However, its exact mode of action remains unclear. To determine whether DSS treatment induces pathogenic changes in the microbiota, we investigated the microbiota-modulating effects of DSS on murine microbiota in vitro. For this purpose, we cultured murine microbiota from the colon in six replicate continuous bioreactors. Three bioreactors were supplemented with 1% DSS and compared with the remaining PBS-treated control bioreactors by means of microbiota taxonomy and functionality. Using metaproteomics, we did not identify significant changes in microbial taxonomy, either at the phylum or genus levels. No differences in the metabolic pathways were observed. Furthermore, the global metabolome and targeted short-chain fatty acid (SCFA) quantification did not reveal any DSS-related changes. DSS had negligible effects on microbial functionality and taxonomy in vitro in the absence of the host environment. Our results underline that the DSS colitis mouse model is a suitable model to study host-microbiota interactions, which may help to understand how intestinal inflammation modulates the microbiota at the taxonomic and functional levels.

01 Dec 2024·Molecular biology reports

Effects of Sichuan pepper (huājiāo) powder on disease activity and caecal microbiota of dextran sodium sulphate-induced inflammatory bowel disease mouse model

Article

Author: Miyashita, Ayumi ; Kuda, Takashi ; Xia, Yumeng ; Takahashi, Hajime ; Nakamura, Ayaka ; Yamamoto, Mahiro

BACKGROUND:

Sichuan pepper [Zanthoxylum bungeanum; huājiāo (HJ)] is a widely used spice in China and has better antioxidative, anti-glycation, and bile acid-lowering properties than cumin and coriander seeds. HJ affects inflammation-related cytokines and caecal microbiota in mice fed a low-fibre and high-sucrose diet.

METHODS AND RESULTS:

To determine the ameliorative effect of HJ on inflammatory bowel disease, C57BL/6 mice were divided into three groups and fed distilled water (control) or 3% (w/v) dextran sodium sulphate (DSS) in drinking water with normal chow containing 0% or 5% (w/w) HJ powder for seven days. After 6 days of feeding, diarrhoea, decreased body weight, and blood in faeces were observed in the DSS group. DSS treatment increased the spleen weight and damaged the colon tissue. These inflammatory indices were inhibited by HJ treatment. Amplicon sequencing of the 16S rDNA (V4) gene of the caecal content revealed a decrease in the alpha diversity (Simpson index D) in the DSS treatment group compared to the control group. The abundance of caecal Desulfovibrio, an inflammation-related genus, was higher and the caecal Lachnospiraceae and Bacteroides levels were lower in the DSS-treated mice than those in the control mice. However, HJ suppressed the DSS-induced changes in the caecal microbiota.

CONCLUSION:

HJ intake contributes to the reduction in inflammation and maintenance of the gut microbiota. However, the strong antioxidant properties of phenolic compounds and fermentability of water-soluble dietary fibres in HJ and their relationship with other functional properties warrant further investigation.

01 May 2024·Journal of ethnopharmacology

Study on the ameliorative effect of honeysuckle on DSS-induced ulcerative colitis in mice

Article

Author: Wu, Zhenfeng ; Leng, Jinglv ; Liao, Zhenggen ; Zang, Zhengzhong ; Zhang, Hua ; Guan, Yongmei ; Li, Liqin ; Zhang, Yuwei ; Naeem, Abid ; Tao, Ling ; Zheng, Qin ; Yang, Ming ; Wan, Zhiyan ; Song, Yonggui

ETHNOPHARMACOLOGICAL RELEVANCE:

Honeysuckle, first documented in the Miscellaneous Records of Famous Physicians, is known for its ability to expel toxin and cool blood to stop diarrhea. Modern pharmacological research has shown that honeysuckle has anti-inflammatory, antibacterial, antioxidant, and immune-regulating effects and is widely used in clinical practice. However, the effect of honeysuckle on ulcerative colitis (UC) is still not fully understood, which presents challenges for quality control, research and development.

AIM OF THE STUDY:

This study aimed to determine the anti-inflammatory properties and mechanism of action of aqueous extracts of honeysuckle in the treatment of ulcerative colitis.

MATERIALS AND METHODS:

The dextran sodium sulfate (DSS) induced-ulcerative colitis mouse model was established, and the mice were divided into five groups: the control group, the model group, and the low, medium, and high dose honeysuckle treatment groups.

RESULTS:

All dose groups of honeysuckle were found to significantly reduce IL-6 and TNF-α levels and regulate DSS-induced mRNA levels of CLDN4, COX-2, IL-6, INOS, MUC-2, occludin and NLRP3. The high-dose group displayed the most effective inhibition, and a differentially expressed mRNA detection indicated abnormal mRNA expression. The 16sRNA sequencing revealed that the honeysuckle was able to significantly upregulate the abundance of beneficial bacteria and downregulate the abundance of harmful bacteria. The study of short-chain fatty acids revealed that the levels of acetic, propionic, isobutyric, valeric and isovaleric acids were significantly increased after administering honeysuckle at medium and high doses.

CONCLUSION:

Honeysuckle reduces the production of pro-inflammatory cytokines, increases the content of short-chain fatty acids and restores the intestinal ecological balance, resulting in better therapeutic effects.

News (Medical) associated with Dioctyl Sodium Sulfosuccinate

21 May 2024

·www.biospace.com

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in Ulcerative Colitis (UC) patients Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of UC before year end Carlsbad, CA, May 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from PALI-2108, an orally administered, locally acting colon-specific Phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC, at DDW 2024 being held in Washington, D.C., May 18-21, 2024. The poster titled, “Local Bioactivation and efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment,” is being presented by Dr. Mitch Jones as part of the Animal Models of IBD: Pre-Clinical Treatment of Intestinal Inflammation session being held today, May 21, 2024. The poster is available on the Scientific Publications page of the Company’s website. “The findings from this preclinical study add to our growing body of encouraging data for PALI-2108 and further bolster our confidence in its potential in the treatment of UC,” commented Dr. Mitch Jones, CMO of Palisade Bio. “Based on the data demonstrated to date, we believe PALI-2108 has the potential to be the first approved PDE4 inhibitor for UC and importantly, provide a much-needed solution for patients.” The preclinical data highlighted in the poster reveal significant advancements in assessing on-target PDE4 binding within colon tissue homogenates when dosed with apremilast, PALI-2108, or Vehicle, utilizing a classic cellular thermal shift assay (CETSA) to detect changes in thermal stability. To comprehensively evaluate PALI-2108's efficacy across various doses, researchers employed an acute colitis model in mice induced by 4% DSS in drinking water from Day 1 to Day 8. Mice received twice-daily (BID) treatments of PALI-2108 at 20, 40, and 80 mg/kg/dose BID, while cyclosporin A and apremilast were administered at 40 and 12.5 mg/kg/dose BID, respectively. The assessment of DSS-induced colitis included monitoring Body Weight score, Stool Consistency score, and Fecal Blood score from Day 1 to Day 8, with evaluations conducted 1 to 2 hours post-dosing. Overall disease state was measured using a Disease Activity Index (DAI) score, calculated by pooling the three in-life scores, assessed daily from Days 1 to 8. Furthermore, a single oral dose of the prodrug PALI-2108 at 43 mg/kg and active PALI-0008 at 0.1, 0.3, 1, and 3 mg/kg was administered to dogs, with a focus on monitoring key clinical adverse events, including emesis. Remarkably, the PALI-2108 prodrug prevented emesis observed with lower doses of the PDE4 active moiety in the model, demonstrating an enhanced therapeutic window. Key Findings PALI-2108 demonstrates similar target engagement to the PDE4 inhibitor, apremilast, which is approved for use in psoriasis and psoriatic arthritis. In a DSS colitis mouse model, PALI-2108 significantly prevented colon length reduction in dose dependent manner, and showed dose dependent improvements in body weight score, stool consistency score, fecal blood score, overall disease activity index (DAI) score, and AUC of DAI over the course of the study. Importantly, PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in UC patients. No systemic toxicity in dogs and large therapeutic window due to local activation. About Palisade Bio Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to . Forward Looking Statements This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of the COVID-19 pandemic or any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company’s ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLC Jenene Thomas 833-475-8247 PALI@jtcir.com Source: Palisade Bio

Clinical ResultPhase 1

22 May 2023

·www.sciencedaily.com

Study may explain why high-sugar diets can worsen IBD

Excess sugar hampers cells that renew the colon's lining in a mouse model of inflammatory bowel disease (IBD), according to a new study that could help get to the bottom of why limiting sugary foods can ease symptoms for patients with IBD. Excess sugar hampers cells that renew the colon's lining in a mouse model of inflammatory bowel disease (IBD), according to a new study by University of Pittsburgh scientists. The findings, published in Cellular and Molecular Gastroenterology and Hepatology, could help get to the bottom of why limiting sugary foods can ease symptoms for patients with IBD. "The prevalence of IBD is rising around the world, and it's rising the fastest in cultures with industrialized, urban lifestyles, which typically have diets high in sugar," said senior author Timothy Hand, Ph.D., associate professor of pediatrics and immunology at Pitt's School of Medicine and UPMC Children's Hospital of Pittsburgh. "Too much sugar isn't good for a variety of reasons, and our study adds to that evidence by showing how sugar may be harmful to the gut. For patients with IBD, high-density sugar -- found in things like soda and candy -- might be something to stay away from." Led by Ansen Burr, Ph.D., a student in Pitt's Medical Scientist Training Program, the researchers started by feeding mice either a standard or high-sugar diet. Then they mimicked symptoms of IBD by treating the animals with a chemical called DSS that causes damage to the colon. To their shock, all the mice on the high-sugar diet died within nine days. In contrast, all the animals on the standard diet survived until the end of the 14-day experiment. To learn what made sugar so deadly in mice with IBD symptoms, the team looked at the animals' colons. Also known as the large intestine, the colon is lined with a layer of epithelial cells that are arranged in finger-like projections called crypts. In a healthy colon, these cells are continually replenished by dividing stem cells at the bottom of each crypt. "The colon epithelium is like a conveyor belt," said Hand, who is also director of Pitt's Gnotobiotic Animal Core Laboratory. "It takes five days for cells to travel through the circuit from the bottom to the top of the crypt, where they are shed into the colon and defecated out. You essentially make a whole new colon every five days." When mice on the high-sugar diet were given DSS, that circuit collapsed, said Hand. In some of the animals, the protective layer of epithelial cells was completely lost, causing the colon to be full of blood and immune cells. Unexpectedly, a high-sugar diet was similarly lethal in germ-free mice treated with DSS, showing that sugar affects the colon directly and is not dependent on the gut microbiome as the researchers had predicted. Next, the team tested how sugar affected mouse and human colonoids, poppy seed-sized miniature intestines that can be grown in a lab dish. As concentrations of glucose, sucrose or fructose increased, fewer colonoids developed and they grew slower, evidence that sugar impaired cell division. "We found that stem cells were dividing much more slowly in the presence of sugar -- likely too slow to repair damage to the colon," said Hand. "The other strange thing we noticed was that the metabolism of the cells was different. These cells usually prefer to use fatty acids, but after being grown in high-sugar conditions, they seemed to get locked into using sugar." In sugary conditions, the cells had vastly altered metabolic pathways, and they produced lower levels of ATP, the energy-providing molecule that drives cellular processes. The researchers suspect that this rewiring of cellular pathways inhibits the capacity of stem cells to divide, slowing renewal of the colon lining and accelerating gut damage in IBD. According to Hand, these findings could help explain other research that has linked sweetened beverages, including sodas, soft drinks and juices, to negative outcomes in IBD patients. "If you eat an apple or an orange, you're eating a lot of sugar, but that sugar is tied up in the fruit's cells, so it takes a long time to digest and open up those cells to get the sugar," said Hand. "Whereas if you drink a soda, the sugar is available almost the second it hits your intestine, and it's easy to drink a huge amount of sugar in a very short time. Our research suggests that consuming high levels of sugar could have negative outcomes for repairing the colon in patients with inflammatory bowel disease." Hand said that future research, done in in collaboration with coauthor Semir Beyaz, Ph.D., assistant professor at Cold Spring Harbor Laboratory, will focus on understanding how diet and immune response can affect IBD. "I think that we need to investigate more deeply what diets are going to benefit patients who have intestinal damage, whether that be from IBD or from radiation therapy to treat colon cancer," said Hand. "It's about a nutraceutical approach to colon damage, or the idea of finding the right diet for a particular patient." Other authors on the study were Junyi Ji, B.Med., of Tsinghua University; Kadir Ozler, B.S., Onur Eskiocak, B.S., and Brian Yueh, B.S., of Cold Spring Harbor Laboratory; and Heather L. Mentrup, Ph.D., Rachel Cumberland, B.A., Ashley V. Menk, B.S., Natalie Rittenhouse, B.S., Chris W. Marshall, Ph.D., Pailin Chiaranunt, B.S., Xiaoyi Zhang, M.D., Ph.D., Lauren Mullinax, M.D., Abigail Overacre-Delgoffe, Ph.D., Vaughn S. Cooper, Ph.D., Amanda C. Poholek, Ph.D., Greg M. Delgoffe, Ph.D., and Kevin P. Mollen, M.D., all of Pitt or UPMC. This work was supported by the Richard King Mellon Institute for Pediatric Research, the National Institutes of Health (T32AI089443-10), the Damon Runyon Cancer Research Foundation (2360-19), the Kenneth Rainin Foundation and the Cancer Center Support Grant (5P30CA045508).

29 Oct 2019

·www.globenewswire.com

The global dioctyl maleate market was valued at $242.6 million in 2018, and is projected to reach $326.1 million by 2026, growing at a CAGR of 3.7% from 2019 to 2026

New York, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Dioctyl Maleate Market by End Use : Global Opportunity Analysis and Industry Forecast, 2019-2026" - The global dioctyl maleate market was valued at $242.6 million in 2018, and is projected to reach $326.1 million by 2026, growing at a CAGR of 3.7% from 2019 to 2026. Dioctyl maleate (DOM) is a maleic acid, which acts as a non-phthalate plasticizer, and is used in resins to provide flexibility and elasticity. These types of polymerizations with dioctyl maleate occur during the production of adhesives, emulsion paints, surfactants, textile coatings, and wetting agents. In particular, DOM is used as a chemical intermediate in the production of surfactant sodium dioctyl sulfosuccinate, which is a used as a wetting agent for detergent. The growth of the global dioctyl maleate market is majorly driven by increase in demand for surfactants, which find their application across industries such as soaps & detergents, personal care, lubricants and fuel additives, industry & institutional cleaning, food processing, and oilfield chemicals. In addition, DOM is applicable in the manufacture of sulfosuccinates, which are used as wetting agents for detergent applications. DOM acts as a non-phthalate plasticizer, and is used in automobiles to join the various parts, thereby replacing the use of metal nuts & bolts and reducing the overall weight of the vehicle. Increase in the demand for lightweight and higher fuel-efficient vehicles is expected to boost the demand for non-phthalate plasticizers, which in turn will drive the growth of the global dioctyl maleate market. Moreover, upsurge in demand for packaged food by consumers owing to hectic schedule and changes in eating habits is expected to augment the need for food contact cling films. This is attributed to significantly contribute toward the growth of global market, as dioctyl maleate is used in the manufacturing of food contact cling films. The demand for food contact cling films is further anticipated to grow at a considerable rate, as they enhance the shelf life of food products. However, availability of large number of substitutes such as dioctyl phthalate (DOP), dioctyl adipate (DOA), and dibutyl maleate (DBM) at lower prices is expected to hinder the growth of this market. On the contrary, implementation of stringent government regulations on usage of phthalates is expected to offer lucrative opportunity for market expansion, as dioctyl maleate acts as non-phthalate plasticizer, which is nontoxic in nature. The global dioctyl maleate market is segmented based on end use and region. Depending on end use, the market is classified into adhesives, emulsion paint, surfactants & wetting agent, plasticizer, textile coating, and others. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, Spain, UK, and rest of Europe), Asia-Pacific (China, India, Japan, South Korea, India, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). The key players operating in the dioctyl maleate industry include Biesterfield AG, Celanese Corporation, ESIM Chemicals, HallStar, Hangzhou Qianyang Technology Co., Ltd, Henan GP Chemicals Co., Ltd., Merck KGaA, Polynt SpA, Shandong Yuanli Science and Technology Co., Ltd., and Tokyo Chemical Industry Co., Ltd. KEY BENEFITS FOR STAKEHOLDERS • Porter’s five forces analysis helps analyze the potential of buyers & suppliers and the competitive scenario of the industry for strategy building. • It outlines the current trends and future scenario of the market from 2019 to 2026 to understand the prevailing opportunities and potential investment pockets. • Major countries in the region have been mapped according to their individual revenue contribution to the regional market. • The key drivers, restraints, and opportunities and their detailed impact analysis are elucidated in the study. • The profiles of key players along with their key strategic developments are enlisted in the report. KEY MARKET SEGMENTS • By End Use • Adhesives, • Emulsion paint • Surfactants & wetting agent • Plasticizer • Textile coating • Others • By Region • North America o U.S. o Canada o Mexico • Europe o Germany o France o Italy o Spain o UK o Rest of Europe • Asia-Pacific o China o Japan o India o South Korea o Rest of Asia-Pacific • LAMEA o Brazil o Saudi Arabia o South Africa o Rest of LAMEA Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

100 Deals associated with Dioctyl Sodium Sulfosuccinate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Dioctyl Sodium Sulfosuccinate	A06AA02	DB11089

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Constipation	-	-	-
Hemorrhoids	-	-	-
Pharmaceutical aids	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Herpes Simplex	Phase 2	US	Meditech Pharmaceuticals, Inc.	-
Acne Vulgaris	Preclinical	US	Meditech Pharmaceuticals, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02977286 (CTgov)	Phase 4	Constipation	12	Polyethylene Glycols+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Naloxegol Oral Tablet+Methylnaltrexone (Naloxegol Oral Tablet)	ncuurspxav(gvmqornzzb) = nwofctepds adfeaozlwn (wpocunbnsk, byalgupfzc - ackztainzc) View more	-	16 Feb 2023
				Placebo Oral Tablet+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Methylnaltrexone (Placebo Oral Tablet)	ncuurspxav(gvmqornzzb) = kznspcjkqo adfeaozlwn (wpocunbnsk, rjztrrpwda - cbxhbsusqq) View more
NCT03523715 (CTgov)	Phase 4	Constipation	77	Prunes+Docusate Sodium (Prunes)	tynaodkpsb(kwhgrsorta) = zvwrrrfiyh zfkciopvcw (tjnplwwbhl, gwkutdccny - gvqbmkckmg) View more	-	08 Apr 2021
				Docusate Sodium (Control)	tynaodkpsb(kwhgrsorta) = dkqvgvrjfw zfkciopvcw (tjnplwwbhl, crgsywmfjc - smntmnkirb) View more
NCT01044212 (CTgov)	Not Applicable	Intestinal Diseases	72	Polyethylene glycol+Dulcolax+Colace	igopgzknzg(izqdcotbde) = dwfisjtjws tzrhiwgyof (ffptpmptkk, krslccytao - bwprnzdcti) View more	-	21 Oct 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis